-resized.jpeg)
Primary Biliary Cholangitis on the Cusp of a New Era of Therapies - Update on Disease Recognition, Diagnosis, and Management
Released On
January 18, 2023
Expires On
January 18, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Dermatology, Endocrinology, Gastroenterology, Hepatology, Pharmacy, Primary Care, Radiology, Rheumatology
Topic(s)
Liver Disease
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by P2P Syncro and Postgraduate Institute for Medicine.
This activity is supported by an educational grant from Ipsen Biopharmaceuticals.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
- Physician Assistants — 1.0 CE Credit
- Pharmacists — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Healthcare providers in gastroenterology, hepatology, primary care, dermatology, radiology, and rheumatology.
Program Overview
In this program on the update of primary biliary cholangits (PBC), message from faculty to primary care providers (e.g., check ALP in those with fatigue and/or pruritus) and gastroenterologists (e.g., start second line therapy if ALP is not normalized) is highlighted. Faculty dialogue on emerging therapies and implications of recent OCA restrictions is included. Case of PBC patient with elevated AMA but normal ALP is discussed.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe patient evaluation, diagnostic approach, and risk stratification in primary biliary cholangitis.
- Review strategies of using UDCA and OCA in practice as well as guideline update on OCA and fibrates.
- Assess the mechanisms of investigational therapies, data from Phase 2 studies, and trials available.
Faculty
Kris V. Kowdley, MD
Dr. Kris Kowdley is the Director of the Liver Care Network and Organ Care Research at Swedish Medical Center. He is on clinical faculty at Washington State University, Elson S. Floyd College of Medicine.
Dr. Kowdley is an internationally recognized leader in the field of hepatology. He has conducted both translational and clinical research and authored more than 400 articles and book chapters. He contributed to the development of breakthrough therapies that meet the unmet need of patients with liver disease including primary biliary cholangitis.
Raj K. Vuppalanchi, MD
Dr. Raj Vuppalanchi is the Director of Clinical Hepatology at IU Health and Professor of Medicine at Indiana University School of Medicine.
Dr. Vuppalanchi is trained in both gastroenterology-hepatology and clinical pharmacology. He has published extensively on various aspects of liver disease that include novel tools in disease evaluation and new therapies in management. He is the lead investigator of a clinical trial that studied a PPAR agonist in the treatment of primary biliary cholangitis.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-22-493-H05-P. Type of Activity: Knowledge
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until Jan 10, 2024 . PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
- Kris Kowdley, MD
-
- Consulting: CymaBay, Enanta, Genfit, Gilead, HighTide, Inipharm, Intercept, Madrigal, Mirum, NGM, Pfizer, and 89bio
- Research support: Corcept, CymaBay, Genfit, Gilead, GSK, Hanmi, Intercept, Madrigal, Mirum, Novo Nordisk, NGM, Pfizer, Pliant, Terns, Viking, and 89bio
- Stock options: Inipharm
- Speaker Bureau: AbbVie, Gilead, Intercept
- Raj Vuppalanchi, MD
-
- Consulting: Echosens.
The PIM planners and others have nothing to disclose. The P2P Syncro planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine (PIM) requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: inquiries@pimed.com.